Home » Archive by Category

Syndication

Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round

November 18, 2014 – 6:00 am | Edit Post

SAN DIEGO, Nov. 18, 2014 /PRNewswire-USNewswire/ – Renova Therapeutics, a biopharmaceutical company developing gene therapy treatments for congestive heart failure and other chronic diseases, announced that Daniel M. Bradbury joined its board of directors. The company also completed its third round of funding, raising $7.52 million.

New board member brings decades of life science experience

Mr. Bradbury is a life sciences executive with more than 30 years of experience in creating transformative business strategies, bringing novel medicines to market and maximizing shareholder value. He is Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm, and the former President and Chief Executive Officer of Amylin Pharmaceuticals, a biopharmaceutical company focused on metabolic diseases.

“I am excited to join the Renova Therapeutics board,” said Mr. Bradbury. “The company’s gene therapy work is transformational, and their potential for success is great.  Renova is poised to help millions of people suffering from congestive heart failure by positively impacting patient outcomes.”

Mr. Bradbury was CEO of Amylin, which was listed on the Nasdaq 100, from March 2007 until Bristol-Myers Squibb acquired the company for $7 billion in August 2012. During Mr. Bradbury’s 18 years at the company, Amylin launched the first once-a-week diabetes therapy and three other first-in-class medicines.

Mr. Bradbury received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. He joins the following directors of the Renova Therapeutics board:

Jack W. Reich, Ph.D., CEO and Co-founder of Renova TherapeuticsRoy Cosan, President of Renova TherapeuticsH. Kirk Hammond, MD, Professor of Medicine, University of California, San Diego, and Co-founder of Renova TherapeuticsCraig Andrews, COO, Co-founder and Secretary of Renova TherapeuticsAndy Noorda, Managing Member of The Canopy GroupMichael Torres, CEO of Adelante Capital Management

Company now funded through 2016

Renova Therapeutics completed its third round of funding on Sept. 30, 2014, raising $7.52 million through a Series C Preferred Stock financing round. Investments in the company have come primarily from high net-worth individuals. The company is funded through 2016.

About Renova Therapeutics

There are more than 32 deaths per hour from congestive heart failure in the United States. Renova Therapeutics is working to change that.

Renova Therapeutics is a San Diego-based biopharmaceutical company and an industry leader in gene therapy, pursuing the development of treatments for congestive heart failure (CHF) and other chronic diseases. CHF is the most rapidly growing cardiovascular disorder in the United States, with an estimated six million people afflicted and 550,000 new cases diagnosed every year. Approximately 26 million patients have CHF worldwide. Renova Therapeutics, in a Public-Private Partnership with the National Institutes of Health, is currently supporting a Phase I/II trial of its novel lead therapy for patients with severe CHF (Class II, III and IV). This initial product is a single-dose gene therapy that, in animal studies, has shown substantially improved, sustained outcomes in heart failure models by safely and significantly improving myocardial function. The product is being evaluated for its safety and initial efficacy in a 3:1 randomized, double-blinded, placebo-controlled dose-ranging study involving 56 patients across seven US medical centers. The company’s product pipeline also includes a second-generation therapy for CHF patients and a groundbreaking therapy in pre-clinical stage for sufferers of Type II diabetes. Renova Therapeutics was founded in 2009 and is led by an experienced management team that co-founded the first publicly traded cardiovascular gene therapy company, Collateral Therapeutics.

Photo – http://photos.prnewswire.com/prnh/20141117/159100
SOURCE Renova Therapeutics

Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round

November 18, 2014 – 6:00 am | Edit Post

SAN DIEGO, Nov. 18, 2014 /PRNewswire-USNewswire/ – Renova Therapeutics, a biopharmaceutical company developing gene therapy treatments for congestive heart failure and other chronic diseases, announced that Daniel M. Bradbury joined its board of directors. The company also completed its third round of funding, raising $7.52 million.

New board member brings decades of life science experience

Mr. Bradbury is a life sciences executive with more than 30 years of experience in creating transformative business strategies, bringing novel medicines to market and maximizing shareholder value. He is Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm, and the former President and Chief Executive Officer of Amylin Pharmaceuticals, a biopharmaceutical company focused on metabolic diseases.

“I am excited to join the Renova Therapeutics board,” said Mr. Bradbury. “The company’s gene therapy work is transformational, and their potential for success is great.  Renova is poised to help millions of people suffering from congestive heart failure by positively impacting patient outcomes.”

Mr. Bradbury was CEO of Amylin, which was listed on the Nasdaq 100, from March 2007 until Bristol-Myers Squibb acquired the company for $7 billion in August 2012. During Mr. Bradbury’s 18 years at the company, Amylin launched the first once-a-week diabetes therapy and three other first-in-class medicines.

Mr. Bradbury received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. He joins the following directors of the Renova Therapeutics board:

Jack W. Reich, Ph.D., CEO and Co-founder of Renova TherapeuticsRoy Cosan, President of Renova TherapeuticsH. Kirk Hammond, MD, Professor of Medicine, University of California, San Diego, and Co-founder of Renova TherapeuticsCraig Andrews, COO, Co-founder and Secretary of Renova TherapeuticsAndy Noorda, Managing Member of The Canopy GroupMichael Torres, CEO of Adelante Capital Management

Company now funded through 2016

Renova Therapeutics completed its third round of funding on Sept. 30, 2014, raising $7.52 million through a Series C Preferred Stock financing round. Investments in the company have come primarily from high net-worth individuals. The company is funded through 2016.

About Renova Therapeutics

There are more than 32 deaths per hour from congestive heart failure in the United States. Renova Therapeutics is working to change that.

Renova Therapeutics is a San Diego-based biopharmaceutical company and an industry leader in gene therapy, pursuing the development of treatments for congestive heart failure (CHF) and other chronic diseases. CHF is the most rapidly growing cardiovascular disorder in the United States, with an estimated six million people afflicted and 550,000 new cases diagnosed every year. Approximately 26 million patients have CHF worldwide. Renova Therapeutics, in a Public-Private Partnership with the National Institutes of Health, is currently supporting a Phase I/II trial of its novel lead therapy for patients with severe CHF (Class II, III and IV). This initial product is a single-dose gene therapy that, in animal studies, has shown substantially improved, sustained outcomes in heart failure models by safely and significantly improving myocardial function. The product is being evaluated for its safety and initial efficacy in a 3:1 randomized, double-blinded, placebo-controlled dose-ranging study involving 56 patients across seven US medical centers. The company’s product pipeline also includes a second-generation therapy for CHF patients and a groundbreaking therapy in pre-clinical stage for sufferers of Type II diabetes. Renova Therapeutics was founded in 2009 and is led by an experienced management team that co-founded the first publicly traded cardiovascular gene therapy company, Collateral Therapeutics.

Photo – http://photos.prnewswire.com/prnh/20141117/159100
SOURCE Renova Therapeutics

The Dirty Side Of Soap, University of California, San Diego (UCSD) Study

November 18, 2014 – 5:00 am | Edit Post

The Dirty Side Of SoapTriclosan, a common antimicrobial in personal hygiene products, causes liver fibrosis and cancer in mice Triclosan is an antimicrobial commonly found in soaps, shampoos, toothpastes and many other household items. Despite its widespread use, researchers at University of California, San Diego School of Medicine report potentially…

Aurora Spine Receives FDA 510(k) Clearance For Pre-Packaged Sterile ZIP 51(TM) MIS Interspinous Fixation Implant

November 18, 2014 – 5:00 am | Edit Post

Aurora Spine Receives FDA 510(k) Clearance for Pre-Packaged Sterile ZIP 51(TM) MIS Interspinous Fixation ImplantCARLSBAD, CALIFORNIA–(Marketwired – Nov 18, 2014) – Aurora Spine Corporation (TSX VENTURE:ASG) announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ZIP 51, Aurora Spine’s slimmest minimally invasive…

Renova Therapeutics Welcomes New Board Member, Raises $7.52 Million In Series C Financing Round

November 18, 2014 – 5:00 am | Edit Post

Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing roundSAN DIEGO, Nov. 18, 2014 /PRNewswire-USNewswire/ –Renova Therapeutics, a biopharmaceutical company developing gene therapy treatments for congestive heart failure and other chronic…

Breaking Bottlenecks, Opening the Floodgates to Genomic Data

November 18, 2014 – 4:00 am | Edit Post

There is a major transformational step underway for managing the growing amount of human genomic data. To date, the focus has been on amassing databanks of genomes and then developing new tools to…

[[Click headline to continue reading.]]

Sr. Clinical Trial Manager – BioPhase Solutions – San Diego, CA

November 18, 2014 – 2:35 am | Edit Post

Clinical Trial Manager to work for a leading San Diego biotechnology company. Bio….
From BioPhase Solutions – 18 Nov 2014 09:35:11 GMT
– View all San Diego jobs

Sr. Manager, Regulatory Affairs – BioPhase Solutions – San Diego, CA

November 18, 2014 – 2:35 am | Edit Post

Manager, Regulatory Affairs to work for a leading San Diego biotechnology company. Bio….
From BioPhase Solutions – 18 Nov 2014 09:35:08 GMT
– View all San Diego jobs

Sales Engineer

November 18, 2014 – 2:10 am | Edit Post

CA-San Diego, Strong networker needed for expansion opportunity within #1 manufacturing company due to rapid growth. Competitive salary and quarterly bonus plan! Monster has partnered with a manufacturer of pneumatic and electromechanical systems, components and controls for process control and factory automation solutions. We need a Sales Engineer that enjoys networking to focus on their biotech and pharmaceut

Patent Agent/Advisor with Biotech degree – S8LL82652 – BCG Attorney Search – San Diego, CA

November 18, 2014 – 1:39 am | Edit Post

In a biotechnology related to join the busy life sciences focused patent counseling, prosecution, and litigation practice….
From BCG Attorney Search – 18 Nov 2014 08:39:13 GMT
– View all San Diego jobs